Why Thai FDA Rejects Drug Registration Applications: 8 Common Reasons

Introduction

A drug registration rejection or major deficiency notice from Thailand FDA can set a product launch back by 12–24 months. Understanding the most common failure modes is essential for dossier preparation and submission strategy.

Reason 1: Incomplete or Missing ACTD Modules

The ACTD dossier has four parts. Thai FDA requires all parts to be present and internally consistent. Common failures include missing analytical method validation reports, incomplete specifications, or absent container-closure system data.

Prevention: Conduct a full ACTD completeness checklist before submission.

Reason 2: Stability Data Not Conducted Under Zone IVb Conditions

Thailand is classified under ICH climatic Zone IVb (40°C / 75% relative humidity). Stability data conducted under Zone IV or Zone II conditions is not acceptable for Thailand FDA registration.

Prevention: Confirm with the Taiwan manufacturer that long-term stability studies are conducted under Zone IVb conditions before initiating a registration project.

Reason 3: GMP Certificate Expired or Not PIC/S-Aligned

Thai FDA requires a valid GMP certificate for the manufacturing site at the time of review. If it expires during the review period and is not renewed, Thai FDA may suspend the review.

Prevention: Track the GMP certificate renewal calendar of your Taiwan manufacturer and request immediate notification when renewal inspections are scheduled.

Reason 4: Bioequivalence Study Issues

Common BE-related deficiencies include: BE study conducted at a non-GCP-accredited facility, wrong reference product used, or statistical analysis failing the 80–125% confidence interval requirement.

Prevention: Confirm the reference product and BE facility acceptability with Thai FDA in advance where possible.

Reason 5: CPP Issues

The CPP must be valid at the time of Thai FDA review. Common issues: expired CPP during review, CPP covering a different strength or dosage form, or CPP not properly apostilled.

Prevention: Monitor CPP validity and request TFDA renewals proactively.

Reason 6: Labeling Non-Compliance

Thai FDA has detailed requirements for product labeling including mandatory Thai-language content. Common deficiencies include missing Thai-language elements and incorrect storage conditions.

Prevention: Have labeling artwork reviewed by a Thai regulatory specialist before submission.

Reason 7: Inconsistencies Between Dossier Sections

Internal inconsistencies between different ACTD parts are a frequent query source — for example, manufacturing process described differently across sections, or stability data showing degradation products not listed in specifications.

Prevention: Assign one person or team to perform a cross-section consistency review before submission.

Reason 8: Slow or Inadequate Query Responses

When Thai FDA issues a query, slow responses or responses that do not fully address the query extend review timelines significantly.

Prevention: Establish a clear communication protocol with your Taiwan manufacturer before submission. Set expectations that query responses will be provided within 4–6 weeks.

Summary Checklist Before Submission

• →Complete ACTD dossier (all parts, all modules)
• →Zone IVb stability data — long-term and accelerated
• →Valid PIC/S GMP certificate (check expiry)
• →Valid CPP from TFDA (check expiry and product scope)
• →BE study from GCP-accredited facility using Thai reference product
• →Thai-language labeling reviewed by regulatory specialist
• →Cross-section dossier consistency review completed
• →Manufacturer query response commitment in place